The Technical AnalystExchange: SHZ Sector: Healthcare Industry: Medical Devices
Wuhan Easy Diagnosis Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.34% CNY20.72
America/New_York / 6 mai 2024 @ 03:04
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 4 817.84 mill |
| EPS: | -0.0200 |
| P/E: | -1 036.00 |
| Earnings Date: | May 17, 2024 |
| SharesOutstanding: | 232.52 mill |
| Avg Daily Volume: | 4.24 mill |
| RATING 2024-05-06 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Neutral | |
| Return On Asset: | Neutral | |
| DE: | Sell | |
| P/E: | Strong Buy | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1 036.00 | sector: PE 35.84 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -25.43x |
| Company: PE -1 036.00 | industry: PE 40.74 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
CNY14.21 (-31.40%) CNY-6.51 |
| Date: 2024-05-06 |
| Expected Trading Range (DAY) |
|---|
|
CNY 19.91 - 21.65 ( +/- 4.18%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | CNY20.72 (-0.34% ) |
| Volume | 4.43 mill |
| Avg. Vol. | 4.24 mill |
| % of Avg. Vol | 104.34 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For 002932.SZ
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
002932.SZ
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. engages in the research and development, production, and sale of in vitro diagnostic reagents and diagnostic equipment in China and internationally. Its products portfolio includes molecular diagnostic products, such as drug metabolism genetic testing and pathogen nucleic acid detection kits; and immunodiagnostic and blood gas diagnosis products. The company also provides emergency and critical illness information solutions, including information software products, supporting hardware, and certification consulting services; and third-party medical inspection services. It offers products in the areas of cardiovascular, kidney, infectious, diabetes, endocrine and metabolic, obstetrics, and gynecology diseases, as well as prenatal and postnatal care, health checkups, thyroid, hormones, blood gas, coagulation, drug metabolism, pathogen detection. The company was founded in 2008 and is based in Wuhan, China.